{"denoms":[{"counts":[{"groupId":"BG000","value":"95"}],"units":"Participants"}],"groups":[{"description":"Cytarabine 1.5 g/m\\^2 and Idarubicin 12 mg/m\\^2 intravenous (IV) continuously on days 1-3 (or 1-4), with Oral Tipifarnib 200/300 twice daily on days 1-21, repeats every 21 days.","id":"BG000","title":"Idarubicin, Cytarabine + Tipifarnib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"17","upperLimit":"61","value":"50"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"53"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"42"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"95"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}